Mast cells respond to cell injury through the recognition of IL-33

Frontiers in Immunology

Volumn 3, Issue APR, 2012, Pages

  Lunderius Andersson, Carolina ^a   Enoksson, Mattias ^a   Nilsson, Gunnar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

IL 33; IL 6; Inflammation; Injury; Mast cell; Migration

Indexed keywords

EID: 84867428809     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00082     Document Type: Review

References (110)

1. Abraham, S. N., and St. John, A. L. (2010). Mast cellorchestrated immunity to pathogens. Nat. Rev. Immunol. 10, 440-452.
2. Ali, S., Huber, M., Kollewe, C., Bischoff, S. C., Falk, W., and Martin, M. U. (2007). IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl. Acad. Sci. U.S.A. 104, 18660-18665.
3. Ali, S., Mohs, A., Thomas, M., Klare, J., Ross, R., Schmitz, M. L., and Martin, M. U. (2011). The dual function cytokine IL-33 interacts with the transcription factor NF{kappa}B To dampen NF-{kappa}Bstimulated gene transcription. J Immunol. 187, 1609-1616.
4. Ali, S., Nguyen, D. Q., Falk, W., and Martin, M. U. (2010). Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem. Biophys. Res. Commun. 391, 1512-1516.
5. Allakhverdi, Z., Comeau, M. R., Jessup, H. K., Yoon, B. R., Brewer, A., Chartier, S., Paquette, N., Ziegler, S. F., Sarfati, M., and Delespesse, G. (2007a). Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J. Exp. Med. 204, 253-258.
6. Allakhverdi, Z., Smith, D. E., Comeau, M. R., and Delespesse, G. (2007b). Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 179, 2051-2054.
7. Alves-Filho, J. C., Sonego, F., Souto, F. O., Freitas, A., Verri, W. A. Jr., Auxiliadora-Martins, M., BasileFilho, A., McKenzie, A. N., Xu, D., Cunha, F. Q., and Liew, F. Y. (2010). Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16, 708-712.
8. Baekkevold, E. S., Roussigne, M., Yamanaka, T., Johansen, F. E., Jahnsen, F. L., Amalric, F., Brandtzaeg, P., Erard, M., Haraldsen, G., and Girard, J. P. (2003). Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69-79.
9. Basu,S.,Binder,R. J.,Suto,R.,Anderson, K. M., and Srivastava, P. K. (2000). Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NFkappa B pathway. Int. Immunol. 12, 1539-1546.
10. Besnard, A. G., Togbe, D., Guillou, N., Erard, F., Quesniaux, V., and Ryffel, B. (2011). IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur. J. Immunol. 41, 1675-1686.
11. Bianchi, M. E. (2007). DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81, 1-5.
12. Bourgeois, E., Van, L. P., Samson, M., Diem, S., Barra, A., Roga, S., Gombert,J. M.,Schneider,E.,Dy,M., Gourdy, P., Girard, J. P., and Herbelin, A. (2009). The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFNgamma production. Eur. J. Immunol. 39, 1046-1055.
13. Bours, M. J., Swennen, E. L., Di Virgilio, F., Cronstein, B. N., and Dagnelie, P. C. (2006). Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112, 358-404.
14. Bradding, P., Walls, A. F., and Holgate, S. T. (2006). The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 117, 1277-1284.
15. Bush, R. K., and Prochnau, J. J. (2004). Alternaria-induced asthma. J. Allergy Clin. Immunol. 113, 227-234.
16. Byrne, S. N., Beaugie, C., O'Ssullivan, C., Leighton, S., and Halliday, G. M. (2011). The immune-modulating cytokine and endogenous alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am. J. Pathol. 179, 211-222.
17. Carriere, V., Roussel, L., Ortega, N., Lacorre, D. A., Americh, L., Aguilar, L., Bouche, G., and Girard, J. P. (2007). IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U.S.A. 104, 282-287.
18. Cayrol, C., and Girard, J. P. (2009). The IL-1-like cytokine IL-33 is inactivated after maturation by caspase1. Proc. Natl. Acad. Sci. U.S.A. 106, 9021-9026.
19. Chackerian, A. A., Oldham, E. R., Murphy, E. E., Schmitz, J., Pflanz, S., and Kastelein, R. A. (2007). IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179, 2551-2555.
20. Chen, C. C., Grimbaldeston, M. A., Tsai, M., Weissman, I. L., and Galli, S. J. (2005). Identification of mast cell progenitors in adult mice. Proc. Natl. Acad. Sci. U.S.A. 102, 11408-11413.
21. Cherry, W. B., Yoon, J., Bartemes, K. R., Iijima, K., and Kita, H. (2008). A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J.Allergy Clin. Immunol. 121, 1484-1490.
22. Di Nardo, A., Vitiello, A., and Gallo, R. L. (2003). Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170, 2274-2278.
23. Dickel, H., Gambichler, T., Kamphowe, J., Altmeyer, P., and Skrygan, M. (2010). Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-alpha and IL-8/CXCL8 mRNA: new insights into the involvement of "alarmins." Contact Derm. 63, 215-222.
24. Eigenbrod, T., Park, J. H., Harder, J., Iwakura, Y., and Nunez, G. (2008). Cutting edge: critical role for mesothelial cells in necrosisinduced inflammation through the recognition of IL-1 alpha released from dying cells. J. Immunol. 181, 8194-8198.
25. Enoksson, M., Lyberg, K., MollerWesterberg, C., Fallon, P. G., Nilsson, G., and Lunderius-Andersson, C. (2011). Mast cells as sensors of cell injury through IL-33 recognition. J. Immunol. 186, 2523-2528.
26. Fischer, M., Harvima, I. T., Carvalho, R. F. S., Moller, C., Naukkarinen, A., Enblad, G., and Nilsson, G. (2006). Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulationindependent chemokine secretion. J. Clin. Invest. 116, 2748-2756.
27. Fujita, J., Nakayama, H., Onoue, H., Kanakura, Y., Nakano, T., Asai, H., Takeda, S., Honjo, T., and Kitamura, Y. (1988). Fibroblastdependent growth of mouse mast cells in vitro: duplication of mast cell depletion in mutant mice of W/Wv genotype. J. Cell. Physiol. 134, 78-84.
28. Funakoshi-Tago, M., Tago, K., Hayakawa, M., Tominaga, S., Ohshio, T., Sonoda, Y., and Kasahara, T. (2008). TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell. Signal. 20, 1679-1686.
29. Funakoshi-Tago, M., Tago, K., Sato, Y., Tominaga, S., and Kasahara, T. (2011). JAK2 is an important signal transducer in IL-33-induced NFkappaB activation. Cell. Signal. 23, 363-370.
30. Galli, S. J., Maurer, M., and Lantz, C. S. (1999). Mast cells as sentinels of innate immunity. Curr. Opin. Immunol. 11, 53-59.
31. Goh, F. G., and Midwood, K. S. (2011). Intrinsic danger: activation of Tolllike receptors in rheumatoid arthritis. Rheumatol. (Oxf.). 51, 7-23.
32. Harvima, I. T., and Nilsson, G. (2011). Mast cells as regulators of skin inflammation and immunity. Acta Derm. Venereol. 91, 644-650.
33. Hayakawa, M., Hayakawa, H., Matsuyama, Y., Tamemoto, H., Okazaki, H., and Tominaga, S. (2009). Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem. Biophys. Res. Commun. 387, 218-222.
34. Ho, L. H., Ohno, T., Oboki, K., Kajiwara, N., Suto, H., Iikura, M., Okayama, Y., Akira, S., Saito, H., Galli, S. J., and Nakae, S. (2007). IL-33 induces IL-13 production by mouse mast cells independently of IgEFcepsilonRI signals. J. Leukoc. Biol. 82, 1481-1490.
35. Hsu, C. L., Neilsen, C. V., and Bryce, P. J. (2010). IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE 5, e11944. doi:10.1371/journal.pone.0011944
36. Hueber, A. J., Alves-Filho, J. C., Asquith, D. L.,Michels,C.,Millar,N. L.,Reilly, J. H.,Graham,G. J.,Liew,F.Y.,Miller, A. M., and McInnes, I. B. (2011). IL33 induces skin inflammation with mast cell and neutrophil activation. Eur. J. Immunol. 41, 2229-2237.
37. Humphreys, N. E., Xu, D., Hepworth, M. R., Liew, F. Y., and Grencis, R. K. (2008). IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 180, 2443-2449.
38. Iikura,M.,Suto,H.,Kajiwara,N.,Oboki, K., Ohno, T., Okayama, Y., Saito, H., Galli, S. J., and Nakae, S. (2007). IL33 can promote survival, adhesion and cytokine production in human mast cells. Lab. Invest. 87, 971-978.
39. Kageyama, Y., Torikai, E., Tsujimura, K., and Kobayashi, M. (2011). Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Mod Rheumatol. 22, 89-93.
40. Nigrovic, P. A., Seki, K., Lee, R. T., Stevens, R. L., aKaieda, S., Shin, K.,nd Lee, D. M. (2010). Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J. Biol. Chem. 285, 21478-21486.
41. Kalesnikoff, J., and Galli, S. J. (2008). New developments in mast cell biology. Nat. Immunol. 9, 1215-1223.
42. Kearley, J., Buckland, K. F., Mathie, S. A., and Lloyd, C. M. (2009). Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL33 pathway. Am. J. Respir. Crit. Care Med. 179, 772-781.
43. Kim, H. S., Han, M. S., Chung, K. W., Kim, S., Kim, E., Kim, M. J., Jang, E., Lee, H. A., Youn, J., Akira, S., and Lee, M. S. (2007). Tolllike receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27, 321-333.
44. Kondo, Y., Yoshimoto, T., Yasuda, K., Futatsugi-Yumikura, S., Morimoto, M., Hayashi, N., Hoshino, T., Fujimoto, J., and Nakanishi, K. (2008). Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int. Immunol. 20, 791-800.
45. Kono, H., and Rock, K. L. (2008). How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279-289.
46. Kouzaki, H., Iijima, K., Kobayashi, T., O'Grady, S. M., and Kita, H. (2011). The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J. Immunol. 186, 4375-4387.
47. Kroeger, K. M., Sullivan, B. M., and Locksley, R. M. (2009). IL18 and IL-33 elicit Th2 cytokines from basophils via a MyD88and p38{alpha}-dependent pathway. J Leukoc. Biol. 86, 769-778.
48. Kurowska-Stolarska, M., Kewin, P., Murphy, G., Russo, R. C., Stolarski, B., Garcia, C. C., Komai-Koma, M., Pitman, N., Li, Y., Niedbala, W., McKenzie, A. N., Teixeira, M. M., Liew, F. Y., and Xu, D. (2008). IL33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181, 4780-4790.
49. Leslie, M. (2007). Mast cells show their might. Science 317, 614-616.
50. Leung, B. P., Xu, D., Culshaw, S., McInnes, I. B., and Liew, F. Y. (2004). A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. 173, 145-150.
51. Levi-Schaffer, F.,Austen, K. F., Caulfield, J. P., Hein, A., Bloes, W. F., and Stevens, R. L. (1985). Fibroblasts maintain the phenotype and viability of the rat heparin-containing mast cell in vitro. J. Immunol. 135, 3454-3462.
52. Liew, F. Y., Pitman, N. I., and McInnes, I. B. (2010). Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103-110.
53. Louten, J., Rankin, A. L., Li, Y., Murphy, E. E., Beaumont, M., Moon, C., Bourne, P., McClanahan, T. K., Pflanz, S., and De Waal Malefyt, R. (2011). Endogenous IL-33 enhances Th2 cytokine production and Tcell responses during allergic airway inflammation. Int. Immunol. 23, 307-315.
54. Luthi, A. U., Cullen, S. P., Mcneela, E. A., Duriez, P. J., Afonina, I. S., Sheridan, C.,Brumatti,G.,Taylor,R. C.,Kersse, K., Vandenabeele, P., Lavelle, E. C., and Martin, S. J. (2009). Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98.
55. Manetti, M., Ibba-Manneschi, L., Liakouli, V., Guiducci, S., Milia, A. F., Benelli, G., Marrelli, A., Conforti, M. L., Romano, E., Giacomelli, R., Matucci-Cerinic, M., and Cipriani, P. (2010). The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann. Rheum. Dis. 69, 598-605.
56. Marshall, J. S. (2004). Mast-cell responses to pathogens. Nat. Rev. Immunol. 4, 787-799.
57. Matsuyama, Y., Okazaki, H., Hoshino, M., Onishi, S., Kamata, Y., Nagatani, K., Nagashima, T., Iwamoto, M., Yoshio, T., Ohto-Ozaki, H., Tamemoto, H., Komine, M., Sekiya, H., Tominaga, S. I., and Minota, S. (2011). Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to antitumor necrosis factor: possible association with persistent IL-1beta signaling and a poor clinical response. Rheumatol. Int. doi: 10.1007/s00296011-1854-6. [Epub ahead of print].
58. Matsuyama, Y., Okazaki, H., Tamemoto, H., Kimura, H., Kamata, Y., Nagatani, K., Nagashima, T., Hayakawa, M., Iwamoto, M., Yoshio, T., Tominaga, S., and Minota, S. (2010). Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J. Rheumatol. 37, 18-25.
59. Merrill, J. E., and Scolding, N. J. (1999). Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathol. Appl. Neurobiol. 25, 435-458.
60. Metz, M., and Maurer, M. (2007). Mast cells - key effector cells in immune responses. Trends Immunol. 28, 234-241.
61. Miller, A. M. (2011). Role of IL33 in inflammation and disease. J. Inflamm. (Lond). 8, 22.
62. Miller, A. M., Xu, D., Asquith, D. L., Denby, L., Li, Y., Sattar, N., Baker, A. H., McInnes, I. B., and Liew, F. Y. (2008). IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339-346.
63. Moffatt, M. F., Gut, I. G., Demenais, F., Strachan, D. P., Bouzigon, E., Heath, S., Von Mutius, E., Farrall, M., Lathrop, M., and Cookson,W. O. (2010). A large-scale, consortiumbased genomewide association study of asthma. N.Engl.J.Med.363, 1211-1221.
64. Moritz, D. R., Rodewald, H. R., Gheyselinck, J., and Klemenz, R. (1998). The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J. Immunol. 161, 4866-4874.
65. Moulin, D., Donze, O., Talabot-Ayer, D., Mezin, F., Palmer, G., and Gabay, C. (2007). Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40, 216-225.
66. Moussion, C., Ortega, N., and Girard, J. P. (2008). The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin?" PLoS ONE 3, e3331. doi:10.1371/journal.pone.0003331
67. Mu, R., Huang, H. Q., Li, Y. H., Li, C., Ye, H., and Li, Z. G. (2010). Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J. Rheumatol. 37, 2006-2013.
68. Nakagawa, S., Koomen, C. W., Bos, J. D., and Teunissen, M. B. (1999). Differential modulation of human epidermal Langerhans cell maturation by ultraviolet B radiation. J. Immunol. 163, 5192-5200.
69. Neill, D. R., Wong, S. H., Bellosi, A., Flynn, R. J., Daly, M., Langford, T. K., Bucks, C., Kane, C. M., Fallon, P. G., Pannell, R., Jolin, H. E., and McKenzie,A. N. (2010). Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464, 1367-1370.
70. Nocka, K., Buck, J., Levi, E., and Besmer, P. (1990). Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J. 9, 3287-3294.
71. Oboki, K., Ohno, T., Kajiwara, N., Arae, K., Morita, H., Ishii, A., Nambu, A., Abe, T., Kiyonari, H., Matsumoto, K., Sudo, K., Okumura, K., Saito, H., and Nakae, S. (2010). IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. U.S.A. 107, 18581-18586.
72. Ohno,T.,Oboki,K.,Kajiwara,N.,Morii, E., Aozasa, K., Flavell, R. A., Okumura, K., Saito, H., and Nakae, S. (2009). Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J. Immunol. 183, 7890-7897.
73. Palmer, G., Lipsky, B. P., Smithgall, M. D., Meininger, D., Siu, S., TalabotAyer, D., Gabay, C., and Smith, D. E. (2008). The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 42, 358-364.
74. Palmer, G., Talabot-Ayer, D., Lamacchia, C., Toy, D., Seemayer, C. A.,Viatte, S., Finckh, A., Smith, D. E., and Gabay, C. (2009). Inhibition of interleukin33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60, 738-749.
75. Pecaric-Petkovic, T., Didichenko, S. A., Kaempfer, S., Spiegl, N., and Dahinden, C. A. (2009). Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113, 1526-1534.
76. Prefontaine, D., Lajoie-Kadoch, S., Foley, S., Audusseau, S., Olivenstein, R., Halayko, A. J., Lemiere, C., Martin, J. G., and Hamid, Q. (2009). Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J. Immunol. 183, 5094-5103.
77. Prefontaine, D., Nadigel, J., Chouiali, F., Audusseau, S., Semlali, A., Chakir, J., Martin, J. G., and Hamid, Q. (2010). Increased IL-33 expression by epithelial cells in bronchial asthma. J. Allergy Clin. Immunol. 125, 752-754.
78. Pushparaj, P. N., Tay, H. K., H'ng S, C., Pitman, N., Xu, D., McKenzie, A., Liew, F. Y., and Melendez, A. J. (2009). The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl. Acad. Sci. U.S.A. 106, 9773-9778.
79. Rank, M. A., Kobayashi, T., Kozaki, H., Bartemes, K. R., Squillace, D. L., and Kita, H. (2009). IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 123, 1047-1054.
80. Ribatti, D., and Crivellato, E. (2011). Mast cells, angiogenesis and cancer. Adv. Exp. Med. Biol. 716, 270-288.
81. Sanada, S., Hakuno, D., Higgins, L. J., Schreiter, E. R., McKenzie, A. N., and Lee, R. T. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549.
82. Scaffidi,P.,Misteli,T.,and Bianchi,M. E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195.
83. Scheynius, A., Johansson, C., Buentke, E., Zargari, A., and Linder, M. T. (2002). Atopic eczema/dermatitis syndrome and Malassezia. Int. Arch. Allergy Immunol. 127, 161-169.
84. Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., Gorman, D. M., Bazan, J. F., and Kastelein, R. A. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptorrelated protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490.
85. Schneider, E., Petit-Bertron, A.F., Bricard, R., Levasseur, M., Ramadan, A., Girard, J.P., Herbelin, A., and Dy, M. (2009). IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoieticgrowthfactorproduction.J. Immunol. 183, 3591-3597.
86. Selye, H. (1965). The Mast Cells. Maryland: Waverly Press Inc.
87. Shi, Y., Evans, J. E., and Rock, K. L. (2003). Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521.
88. Shimizu, M., Matsuda, A., Yanagisawa, K., Hirota, T., Akahoshi, M., Inomata, N., Ebe, K., Tanaka, K., Sugiura, H., Nakashima, K., Tamari, M., Takahashi, N., Obara, K., Enomoto, T., Okayama, Y., Gao, P. S., Huang, S. K., Tominaga, S., Ikezawa, Z., and Shirakawa,T. (2005). Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum. Mol. Genet. 14, 2919-2927.
89. Silver, M. R., Margulis, A., Wood, N., Goldman, S. J., Kasaian, M., and Chaudhary, D. (2009). IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm. Res. 59, 207-218.
90. Smithgall, M. D., Comeau, M. R., Yoon, B. R., Kaufman, D., Armitage, R., and Smith, D. E. (2008). IL-33 amplifies both Th1and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20, 1019-1030.
91. Strickland, I., Rhodes, L. E., Flanagan, B. F., and Friedmann, P. S. (1997). TNF-alpha and IL-8 are upregulated in the epidermis of normal human skin after UVB exposure: correlation with neutrophil accumulation and E-selectin expression. J. Invest. Dermatol. 108, 763-768.
92. Suzukawa, M., Iikura, M., Koketsu, R., Nagase, H., Tamura, C., Komiya, A., Nakae, S., Matsushima, K., Ohta, K., Yamamoto, K., and Yamaguchi, M. (2008a). An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J. Immunol. 181, 5981-5989.
93. Suzukawa, M., Koketsu, R., Iikura, M., Nakae, S., Matsumoto, K., Nagase, H., Saito, H., Matsushima, K., Ohta, K., Yamamoto, K., and Yamaguchi, M. (2008b). Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab. Invest. 88, 1245-1253.
94. Tago, K., Noda, T., Hayakawa, M., Iwahana, H., Yanagisawa, K., Yashiro, T., and Tominaga, S. (2001). Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem. Biophys. Res. Commun. 285, 1377-1383.
95. Talabot-Ayer, D., Lamacchia, C., Gabay, C., and Palmer, G. (2009). Interleukin-33 is biologically active independently of caspase1 cleavage. J Biol Chem. 284, 19420-19426.
96. Talabot-Ayer, D., Mckee, T., Gindre, P., Bas, S., Baeten, D. L., Gabay, C., and Palmer, G. (2012). Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 79, 32-37.
97. Theoharides,T. C.,Kempuraj,D.,Tagen, M., Conti, P., and Kalogeromitros, D. (2007). Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev. 217, 65-78.
98. Theoharides, T. C., Zhang, B., Kempuraj, D., Tagen, M., Vasiadi, M., Angelidou, A., Alysandratos, K. D., Kalogeromitros, D., Asadi, S., Stavrianeas, N., Peterson, E., Leeman, S., and Conti, P. (2010). IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. U.S.A. 107, 4448-4453.
99. Tominaga, S. (1989). A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 258, 301-304.
100. Torgerson, D. G., Ampleford, E. J., Chiu, G. Y., Gauderman, W. J., Gignoux, C. R., Graves, P. E., Himes, B. E., Levin, A. M., Mathias, R. A., Hancock, D. B., Baurley, J. W., Eng, C., Stern, D. A., Celedon, J. C., Rafaels, N., Capurso, D., Conti, D. V., Roth, L. A., Soto-Quiros, M., Togias, A., Li, X., Myers, R. A., Romieu, I., Van Den Berg, D. J., Hu, D., Hansel, N. N., Hernandez, R. D., Israel, E., Salam, M. T., Galanter, J., Avila, P. C., Avila, L., Rodriquez-Santana, J. R., Chapela, R., Rodriguez-Cintron, W., Diette, G. B., Adkinson, N. F., Abel, R. A., Ross, K. D., Shi, M., Faruque, M. U., Dunston, G. M., Watson, H. R., Mantese, V. J., Ezurum, S. C., Liang, L., Ruczinski, I., Ford, J. G., Huntsman, S., Chung, K. F., Vora, H., Li, X., Calhoun, W. J., Castro, M., Sienra-Monge, J. J., Del Rio-Navarro, B., Deichmann, K. A., Heinzmann, A., Wenzel, S. E., Busse, W. W., Gern, J. E., Lemanske, R. F. Jr., Beaty, T. H., Bleecker, E. R., Raby, B. A., Meyers, D. A., London, S. J., Gilliland, F. D., Burchard, E. G.,Martinez, F. D., Weiss, S. T., Williams, L. K., Barnes, K. C., Ober, C., and Nicolae, D. L. (2011). Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat. Genet. 43, 887-892.
101. Trajkovic, V., Sweet, M. J., and Xu, D. (2004). T1/ST2 - an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 15, 87-95.
102. Verri,W.A.Jr.,Souto,F.O.,Vieira,S. M., Almeida, S. C., Fukada, S. Y., Xu, D., Alves-Filho, J. C., Cunha, T. M., Guerrero, A. T., Mattos-Guimaraes, R. B., Oliveira, F. R., Teixeira, M. M., Silva, J. S., McInnes, I. B., Ferreira, S. H., Louzada-Junior, P., Liew, F. Y., and Cunha, F. Q. (2010). IL33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann. Rheum. Dis. 69, 1697-1703.
103. Walker,M. E.,Hatfield,J. K.,and Brown, M. A. (2012). New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action? Biochim. Biophys. Acta 1822, 57-65.
104. Weller,K.,Foitzik,K.,Paus,R.,Syska,W., and Maurer, M. (2006). Mast cells are required for normal healing of skin wounds in mice. FASEB J. 20, 2366-2368.
105. West, G. B. (1958). Pharmacology of the tissue mast cell. Br. J. Dermatol. 70, 409-417.
106. Xu, D., Chan, W. L., Leung, B. P., Huang, F., Wheeler, R., Piedrafita, D., Robinson, J. H., and Liew, F. Y. (1998). Selective expression of a stable cell surface molecule on type 2 but not type1helperTcells.J. Exp. Med. 187, 787-794.
107. Xu, D., Jiang, H. R., Kewin, P., Li, Y., Mu, R., Fraser, A. R., Pitman, N., Kurowska-Stolarska, M., McKenzie, A. N., McInnes, I. B., and Liew, F. Y. (2008). IL-33 exacerbates antigeninduced arthritis by activating mast cells. Proc. Natl.Acad. Sci. U.S.A. 105, 10913-10918.
108. Xu, D., Jiang, H. R., Li, Y., Pushparaj, P. N., Kurowska-Stolarska, M., Leung, B. P., Mu, R., Tay, H. K., McKenzie, A. N., McInnes, I. B., Melendez, A. J., and Liew, F. Y. (2010). IL-33 exacerbates autoantibodyinduced arthritis. J. Immunol. 184, 2620-2626.
109. Yanaba, K., Yoshizaki, A., Asano, Y., Kadono, T., and Sato, S. (2011). Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin. Rheumatol. 30, 825-830.
110. Yanagisawa, K., Takagi, T., Tsukamoto, T., Tetsuka, T., and Tominaga, S. (1993). Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin1receptortype1.FEBS Lett. 318, 83-87.